The day in pharma, read in minutes.
NewsIDEAYA Biosciences Secures FDA Type C Alignment on Dual-Track IDE849 Registrational Strategy in Neuroendocrine Carcinomas
IDEAYA Biosciences aligns with FDA on a dual-track IDE849 strategy: single-arm accelerated approval cohort plus concurrent Phase 3 in neuroendocrine carcinomas.
Genentech Gains FDA Approval for Giredestrant Plus Everolimus in Breast Cancer

Cue Biopharma Reports Phase 2 CSU Durability Data and CUE-401 First-in-Human Dosing
Mankind Pharma Signs Exclusive India Deal with Betta Pharmaceuticals

Lantheus Achieves Phase 3 Endpoints for TAUKLARIFY in Early Alzheimer's Disease
Latest news
11 storiesUCB Gains FDA Approval for Klygefa as First Dual-Binding Nanobody C5 Inhibitor
UCB's Klygefa becomes the first dual-binding nanobody C5 inhibitor approved in the US for generalized myasthenia gravis, delivered via subcutaneous autoinjector.

Novartis Gains CHMP Positive Opinion for Cosentyx in Adolescent Hidradenitis Suppurativa
Novartis's Cosentyx receives CHMP positive opinion for adolescent HS, triggering label expansion obligations across batch release, packaging, and pharmacovigilance in Europe.

Evotec Secures $2.9 Million Gates Foundation Grant to Extend Stem Cell-Based Fetal Safety Screening
Evotec receives a $2.9M Gates Foundation grant to extend its hiPSC-based fetal safety screening platform for global health drug programs.

EMA CHMP Recommends Seven Medicines at November 2026 Meeting
CHMP recommends seven new medicines at November 2026 meeting, including two insulin aspart biosimilars and generic ruxolitinib, advancing EU market entry timelines.

Reviva Secures USPTO Track 1 Review for Brilaroxazine
Reviva Pharmaceuticals gains USPTO Track 1 priority examination for a new brilaroxazine formulation patent, with exclusivity potentially extending to 2046.

Sutro Biopharma Advances Three ADC Programs Toward Clinic
Sutro Biopharma advances three site-specific ADC programs toward or into Phase 1, with cell-free conjugation enabling precise DAR control across dual-payload formats.

Immix Biopharma Appoints Dual SVPs Ahead of NXC-201 BLA
Immix Biopharma builds out CMC and regulatory leadership ahead of a mid-2027 NXC-201 BLA submission, with 89% complete response rate data heading to ASH.

Codexis Achieves 100-Gram Oligonucleotide Scale-Up
Codexis scales ECO Synthesis to 100g oligonucleotide output and targets GMP facility readiness by end of 2027 for early clinical siRNA supply.

Eros Apothecary Recalls Honey Supplement Over Tadalafil
Eros Apothecary recalls honey supplement after FDA lab testing detects undeclared tadalafil, flagging e-commerce supply chain oversight gaps.

Artelo Reports 40% Weight Loss with Semaglutide in Mice
Artelo's ART27.13 achieves ~40% weight loss combined with semaglutide in nonclinical model; U.S. patent protection expected through 2041.

Grace Therapeutics Advances Dual-Source CMO Strategy
Grace Therapeutics pursues dual-source CMO strategy for GTx-104 after FDA CRL flags CMC deficiencies, with NDA resubmission tied to whichever site clears readiness first.

Worth your time this week

Monopar Therapeutics Nears Rolling NDA Completion for ALXN1840

Kiora Pharmaceuticals Advances KIO-401 IND Pathway

Johnson & Johnson Secures Second Phase 3 Win for CAPLYTA
